Besides the -cell dysfunction, incretin deficiency is now considered among the key factors in the pathophysiology of T2D
GLP-1 drugs have been used for treating diabetes for around 20 years
Researchers weighing their options should read the complete retatrutide versus semaglutide analysis for detailed mechanistic comparisons
Retrieved on June 15, 2021 from
Key Takeaway Discover the evidence on Zepbound for Hashimoto's thyroiditis
CrossRef An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song Nature Communications .2025;[Epub] CrossRef A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei Hepatitis Monthly .2025;[Epub] CrossRef Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng Virology Journal .2025;[Epub] CrossRef Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research .2025;[Epub] CrossRef 20,447 View 703 Download 25 Web of Science Crossref Viral hepatitis Abstract PDF Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB)
